AI assistant
Sending…
Calliditas Therapeutics — Major Shareholding Notification 2021
Aug 16, 2021
3020_iss_2021-08-16_8ff08197-43ac-4fd4-abe8-8334130ce948.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer

Issuer Calliditas Therapeutics AB
Holder
Swedbank Robur Fonder AB
Instrument
| Instrument | Aktier SE0010441584 | |
|---|---|---|
| Before the transaction | ||
| Shares | 2,168,107 | |
| Voting rights | 2,168,107 | |
| Transaction | ||
| Reason for major shareholding notification New share issue | ||
| Date | 12/08/2021 | |
| Limit for number of shares | 5 % | |
| Limit for number of votes | 5 % | |
| After the transaction | ||
| Quantity | ||
| Shares | 2,818,107 | |
| Directly held voting rights | 2,818,107 | |
| Indirectly held voting rights | 0 | |
| Percentage | ||
| Directly held shares | 5.38 % | |
| Directly held voting rights | 5.38 % | |
| Indirectly held voting rights | 0 % |
Resulting distribution of total holdings
| Percentage of voting rights: |
Number of underlying shares: |
||
|---|---|---|---|
| Shares | 5.38 % | 2,818,107 | |
| Instruments - FITA Ch. 4, section 2, first paragraph, line 2 |
|||
| Instruments - FITA Ch. 4, section 2, first paragraph, line 3 |
|||
| - Physically settled | |||
| - Cash settled | |||
| Total | 5.38 % | 2,818,107 | |
| Notes (other relevant informations according to law) |
Flaggningen baseras på 52 341 584 utestående aktier och röster.
Published
16/08/2021 11:34
Contact
Name Mats Frankeus
Phone 08-58592400 Email [email protected]
CLOSE PRINT
[email protected] Tfn 08-408 980 37 Fax 08-24 39 25
More from Calliditas Therapeutics
Board/Management Information
2024
Sep 30
Declaration of Voting Results & Voting Rights Announcements
2024
Sep 30
Delisting Announcement
2024
Sep 16
Delisting Announcement
2024
Sep 16
Major Shareholding Notification
2024
Sep 13
Major Shareholding Notification
2024
Sep 3
Major Shareholding Notification
2024
Sep 3
Delisting Announcement
2024
Sep 3
Delisting Announcement
2024
Sep 3
Proxy Solicitation & Information Statement
2024
Sep 3